Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study


Conference Paper

Full Text

Duke Authors

Cited Authors

  • DiNardo, CD; De Botton, S; Stein, EM; Roboz, GJ; Mims, AS; Pollyea, DA; Swords, RT; Altman, JK; Collins, RH; Mannis, GN; Uy, GL; Donnellan, W; Pigneux, A; Fathi, AT; Stein, AS; Erba, HP; Prince, GT; Foran, JM; Traer, E; Stuart, RK; Arellano, ML; Slack, JL; Sekeres, MA; Yen, K; Kapsalis, SM; Liu, H; Goldwasser, M; Agresta, S; Attar, EC; Tallman, MS; Stone, RM; Kantarjian, HM

Published Date

  • December 7, 2017

Published In

Volume / Issue

  • 130 /

Published By


  • 5

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 59th Annual Meeting of the American-Society-of-Hematology (ASH)

Conference Location

  • Atlanta, GA

Conference Start Date

  • December 9, 2017

Conference End Date

  • December 12, 2017